These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38576457)

  • 1. Tyrosine phosphatase SHP2 aggravates tumor progression and glycolysis by dephosphorylating PKM2 in gastric cancer.
    Wang P; Han Y; Pan W; Du J; Zuo D; Ba Y; Zhang H
    MedComm (2020); 2024 Apr; 5(4):e527. PubMed ID: 38576457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcription factor LHX9 (LIM Homeobox 9) enhances pyruvate kinase PKM2 activity to induce glycolytic metabolic reprogramming in cancer stem cells, promoting gastric cancer progression.
    Zhao H; Jiang R; Feng Z; Wang X; Zhang C
    J Transl Med; 2023 Nov; 21(1):833. PubMed ID: 37980488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KAT2A Promotes the Succinylation of PKM2 to Inhibit its Activity and Accelerate Glycolysis of Gastric Cancer.
    Zhang C; Huang Z
    Mol Biotechnol; 2024 Jun; 66(6):1446-1457. PubMed ID: 37294531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced expression of the M2 isoform of pyruvate kinase is involved in gastric cancer development by regulating cancer-specific metabolism.
    Shiroki T; Yokoyama M; Tanuma N; Maejima R; Tamai K; Yamaguchi K; Oikawa T; Noguchi T; Miura K; Fujiya T; Shima H; Sato I; Murata-Kamiya N; Hatakeyama M; Iijima K; Shimosegawa T; Satoh K
    Cancer Sci; 2017 May; 108(5):931-940. PubMed ID: 28235245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyruvate kinase M2 contributes to cell growth in gastric cancer via aerobic glycolysis.
    Li H; Xu H; Xing R; Pan Y; Li W; Cui J; Lu Y
    Pathol Res Pract; 2019 Jun; 215(6):152409. PubMed ID: 31000383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
    Tani H; Kurita S; Miyamoto R; Ochiai K; Tamura K; Bonkobara M
    Vet Comp Oncol; 2020 Jun; 18(2):161-168. PubMed ID: 31339650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA VAL facilitates PKM2 enzymatic activity to promote glycolysis and malignancy of gastric cancer.
    Dai T; Zhang X; Zhou X; Hu X; Huang X; Xing F; Tian H; Li Y
    Clin Transl Med; 2022 Oct; 12(10):e1088. PubMed ID: 36229913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty.
    Hanafusa H; Torii S; Yasunaga T; Matsumoto K; Nishida E
    J Biol Chem; 2004 May; 279(22):22992-5. PubMed ID: 15031289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain-containing protein tyrosine phosphatase (SHP2) inhibitor at molecular level through molecular docking and molecular dynamics.
    Wang RR; Liu WS; Zhou L; Ma Y; Wang RL
    J Biomol Struct Dyn; 2020 Mar; 38(5):1525-1538. PubMed ID: 31043123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2
    Du S; Lu XH; Li WY; Li LP; Ma YC; Zhou L; Wu JW; Ma Y; Wang RL
    Mol Divers; 2021 Aug; 25(3):1873-1887. PubMed ID: 33392964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML.
    Pfeiffer A; Franciosa G; Locard-Paulet M; Piga I; Reckzeh K; Vemulapalli V; Blacklow SC; Theilgaard-Mönch K; Jensen LJ; Olsen JV
    Cancer Res; 2022 Jun; 82(11):2141-2155. PubMed ID: 35311954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PKM2 promotes cell migration and inhibits autophagy by mediating PI3K/AKT activation and contributes to the malignant development of gastric cancer.
    Wang C; Jiang J; Ji J; Cai Q; Chen X; Yu Y; Zhu Z; Zhang J
    Sci Rep; 2017 Jun; 7(1):2886. PubMed ID: 28588255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric inhibition of SHP2 uncovers aberrant TLR7 trafficking in aggravating psoriasis.
    Zhu Y; Wu Z; Yan W; Shao F; Ke B; Jiang X; Gao J; Guo W; Lai Y; Ma H; Chen D; Xu Q; Sun Y
    EMBO Mol Med; 2022 Mar; 14(3):e14455. PubMed ID: 34936223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC).
    Karachaliou N; Cardona AF; Bracht JWP; Aldeguer E; Drozdowskyj A; Fernandez-Bruno M; Chaib I; Berenguer J; Santarpia M; Ito M; Codony-Servat J; Rosell R
    EBioMedicine; 2019 Jan; 39():207-214. PubMed ID: 30473379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors.
    Tang K; Zhao M; Wu YH; Wu Q; Wang S; Dong Y; Yu B; Song Y; Liu HM
    Eur J Med Chem; 2022 Feb; 230():114106. PubMed ID: 35063735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric SHP2 inhibition enhances regorafenib's effectiveness in colorectal cancer treatment.
    Han X; Wang W; Wang R; Zhang W; Zhu L; Xu Q; Guo W; Gu Y
    Biochem Biophys Res Commun; 2024 May; 709():149812. PubMed ID: 38564942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies.
    Song Z; Wang M; Ge Y; Chen XP; Xu Z; Sun Y; Xiong XF
    Acta Pharm Sin B; 2021 Jan; 11(1):13-29. PubMed ID: 33532178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors.
    Song Y; Zhao M; Wu Y; Yu B; Liu HM
    Acta Pharm Sin B; 2021 Mar; 11(3):750-762. PubMed ID: 33777680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PKM2-dependent glycolysis promotes the proliferation and migration of vascular smooth muscle cells during atherosclerosis.
    Zhao X; Tan F; Cao X; Cao Z; Li B; Shen Z; Tian Y
    Acta Biochim Biophys Sin (Shanghai); 2020 Jan; 52(1):9-17. PubMed ID: 31867609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.